Gufic BioSciences Ltd logo

Gufic BioSciences Ltd

NSE: GUFICBIO BSE: 509079

₹473.05

-13.95 (2.86%)

Sun, 22 Nov 2026, 03:14 pm

mtf coin illustrationMTF 5xInvest in Gufic BioSciences Ltd with 5x LeverageBuy with MTFpremium button ring illustration
Market Cap (in Cr)4728.82
PE Ratio64.58
Dividend0.02
Health TechnologyHealth Technology
Pharmaceuticals: MajorPharmaceuticals: Major
24.5K24.5K

Gufic BioSciences Analysis

dividend

thumbs up icon

Pros

    thumbs up icon

    Cons

    • Gufic Biosciences is not paying a notable dividend for India, therefore no need to check if the payments are increasing.
    • No need to calculate the sustainability of Gufic Biosciences's dividends as it is not paying a notable one for India.
    • Gufic Biosciences is not paying a notable dividend for India, therefore no need to check if the payments are stable.
    • Gufic Biosciences's pays a lower dividend yield than the bottom 25% of dividend payers in India (0.76%).
    • Gufic Biosciences's dividend is below the markets top 25% of dividend payers in India (3.08%).

    health

    thumbs up icon

    Pros

    • Gufic Biosciences is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
    • Gufic Biosciences is profitable, therefore cash runway is not a concern.
    • Gufic Biosciences is profitable, therefore cash runway is not a concern.
    • Debt is well covered by operating cash flow (24.3%, greater than 20% of total debt).
    • Debt is covered by short term assets, assets are 2.3x debt.
    • Gufic Biosciences's cash and other short term assets cover its long term commitments.
    • Interest payments on debt are well covered by earnings (EBIT is 3.3x coverage).
    thumbs up icon

    Cons

    • The level of debt compared to net worth has increased over the past 5 years (107.4% vs 123.7% today).
    • Gufic Biosciences's level of debt (123.7%) compared to net worth is high (greater than 40%).
    • High level of physical assets or inventory.

    management

    thumbs up icon

    Pros

    • The tenure for the Gufic Biosciences board of directors is about average.
    • Pranav's remuneration is lower than average for companies of similar size in India.
    • Pranav's compensation has been consistent with company performance over the past year, both up more than 20%.
    thumbs up icon

    Cons

      misc

      thumbs up icon

      Pros

        thumbs up icon

        Cons

        • Gufic Biosciences is not covered by any analysts.
        • Gufic Biosciences has significant price volatility in the past 3 months.

        past

        thumbs up icon

        Pros

        • Gufic Biosciences's 1-year earnings growth exceeds its 5-year average (48.7% vs 33.5%)
        • Gufic Biosciences has delivered over 20% year on year earnings growth in the past 5 years.
        • Gufic Biosciences used its assets more efficiently than the IN Pharmaceuticals industry average last year based on Return on Assets.
        • Gufic Biosciences's earnings growth has exceeded the IN Pharmaceuticals industry average in the past year (48.7% vs 22.7%).
        thumbs up icon

        Cons

        • Gufic Biosciences's use of capital deteriorated last year versus 3 years ago (Return on Capital Employed).
        • Whilst Gufic Biosciences has efficiently used shareholders’ funds last year (Return on Equity greater than 20%), this is metric is skewed due to its high level of debt.

        value

        thumbs up icon

        Pros

        • 509079 outperformed the Market in India which returned -14.5% over the past year.
        • BSE:509079 is up 16.2% outperforming the Pharmaceuticals industry which returned 6.8% over the past month.
        • BSE:509079 is up 16.2% outperforming the market in India which returned 8% over the past month.
        thumbs up icon

        Cons

        • Gufic Biosciences's share price is above the future cash flow value, it's not available at a moderate discount (< 20%).
        • Gufic Biosciences's share price is above the future cash flow value, it's not available at a substantial discount (< 40%).
        • Gufic Biosciences is overvalued based on assets compared to the IN Pharmaceuticals industry average.
        • Gufic Biosciences is overvalued based on earnings compared to the IN Pharmaceuticals industry average.
        • Gufic Biosciences is overvalued based on earnings compared to the India market.
        • 509079 underperformed the Pharmaceuticals industry which returned 26.7% over the past year.
        pocketful logo lightpocketful logo dark
        PricingBecome a Partner
        search icon
        /

        No results for ''

        Popular search

        • popular search iconSuzlon Energy Ltd
        • popular search iconIndian Railway Finance Corporation Ltd
        • popular search iconTata Motors Ltd
        • popular search iconTata Steel Ltd
        • popular search iconRail Vikas Nigam Ltd

        Recent search

            Log In
            search icon

            No results for ‘’

              Popular search

              • popular search iconSuzlon Energy Ltd
              • popular search iconIndian Railway Finance Corporation Ltd
              • popular search iconTata Motors Ltd
              • popular search iconTata Steel Ltd
              • popular search iconRail Vikas Nigam Ltd
              • popular search iconReliance Industries Ltd
              pocketful logo lightpocketful logo dark
              • Pricing
              • Become a Partner
              Log In
              • home icon
              • arrow iconstocks
              • arrow icongufic biosciences ltd
              • arrow iconanalysis
              • Overview
              • Analysis
              • Financials
              • Ratios
              • shareholding
              • Technical Analysis
              • Corporate Actions
              • Peer Comparison
              • About
              • Company History
              • Deals
              • News
              • FAQs

              Open Your Free Demat Account Now!

              Step into a world of zero fees and limitless opportunities!

              pocketful logo
              • Quick Links

                • Open Demat Account
                • Pocketful Web
                • Pocketful App
                • Pricing
                • Authorised Person
                • Pocketful Calculators
                • Compliance Links
              • Pages

                • Tools
                • Blogs
                • ETF Screener
                • IPO
                • ETF
                • Bonds
                • Index Heat Map
              • Products

                • Stocks
                • Commodity
                • Subscription
                • Free Stock Screener
                • Pocketful GPT
                • MTF
                • Mutual Funds
              • Company

                • About us
                • Contact us
                • Terms and Conditions
                • Policies & Procedures
                • Privacy Policy
                • Disclosure
                • Careers
              • Socials

                • Facebook iconFacebook
                • Twitter iconTwitter
                • Instagram iconInstagram
                • LinkedIn iconLinkedIn
                • Youtube iconYoutube

              2022-25 Pocketful. All rights reserved, Built with in India

              Version -5.76

              app image 1app image 2

              Stocks:

              AllABCDEFGHIJKLMNOPQRSTUVWXYZ

              Explore

              Calculators
              Popular Calculators
              Group Stocks
              Asset Management Companies
              Popular Stocks
              Indian Indices
              Sector Wise Stocks
              IPO
              Share Market
              Best MF Schemes
              Platforms
              Resources
              Gold Rates in Top Cities
              Silver Rates in Top Cities

              Others:

              NSEBSECDSLNSDLSEBIMCXMSEINCDEXNSE IFSCINDIA INXAccount Closure FormDP Investor CharterBroker Investor Charter

              Pocketful Fintech Capital Private Limited (CIN U65999DL2021PTC390548) | The SEBI Registration No. allotted to us is INZ000313732. NSE Member Code: 90326 | BSE Member Code: 6808 | MCX Member Code: 57120 DP | CDSL: 12099800